Study identifier:D4920C00002
ClinicalTrials.gov identifier:NCT04610892
EudraCT identifier:2020-000840-75
CTIS identifier:N/A
A Phase IIB, Randomized, Double blinded, Placebo controlled, Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction and Persistent Inflammation
Coronary Heart Disease (CHD)
Phase 2
No
-
All
423
Interventional
21 Years - n/a
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Jan 2025 by AstraZeneca
AstraZeneca
Thrombolysis in Myocardial Infarction (TIMI) Study Group
A Phase IIB Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction.
This Phase IIB, proof-of-concept, dose-range finding clinical study is being conducted to evaluate the anti-inflammatory potential of MEDI6570 and its effect on surrogates for atherosclerotic and heart failure (HF) events in patients with a history of myocardial infarction (MI). The results of the Phase IIB study will inform future clinical development options and precision medicine strategy for future clinical studies. Participants will be randomized in a 2:2:1:1 ratio after protocol Amend 2, 360 evaluable participants (111 evaluable participants in each of the 2 MEDI6570 groups, plus 27 evaluable participants in the legacy low dose MEDI6570 group, plus 111 participants in pooled placebo) will complete the study.
Location
Location
Madrid, Spain, 28046
Location
Budapest, Hungary, 1134
Location
Northridge, CA, United States, 91325
Location
Mobile, AL, United States, 36608
Location
Kitakyushu-shi, Japan, 802-8555
Location
Beverly Hills, CA, United States, 90211
Location
Torrance, CA, United States, 90502
Location
Rapid City, SD, United States, 57701
Arms | Assigned Interventions |
---|---|
Experimental: MEDI6570 Low dose Monthly Subcutaneous administration. | Biological/Vaccine: MEDI6570 MEDI6570 Other Name: None |
Experimental: MEDI6570 Medium dose Monthly Subcutaneous administration. | Biological/Vaccine: MEDI6570 MEDI6570 Other Name: None |
Experimental: MEDI6570 High dose Monthly Subcutaneous administration. | Biological/Vaccine: MEDI6570 MEDI6570 Other Name: None |
Placebo Comparator: Placebo Low dose Monthly Subcutaneous administration. | Biological/Vaccine: Placebo Buffer Other Name: None |
Placebo Comparator: Placebo Medium dose Monthly Subcutaneous administration | Biological/Vaccine: Placebo Buffer Other Name: None |
Placebo Comparator: Placebo High dose Monthly Subcutaneous administration | Biological/Vaccine: Placebo Buffer Other Name: None |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.